Braveheart Bio launches with $185M Series A financing
California, USA-based clinical-stage biotech Braveheart Bio has announced its launch with $185 million in Series A financing, which will support development of an investigation treatment for hypertrophic cardiomyopathy.
The deal attracted experienced life science investors Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital), and Frazier Life Sciences participated in the round.
"Current treatments for HCM leave considerable room for improvement," said Dr Travis Murdoch, president and chief executive of Braveheart Bio. "We see potential for our investigational cardiac myosin inhibitor to be a best-in-class molecule that enhances the efficacy, safety, and convenience of care for patients and prescribers. I am delighted to be leading Braveheart's highly talented and expanding team, who share a commitment to making a positive impact for patients," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze